Sanofi signs biomedical collaboration with MIT
pharmafile | May 27, 2010 | News story | Research and Development | MIT, Sanofi-Aventis, academia, biomedical
Sanofi-Aventis has formed a strategic alliance with the Centre for Biodmedical Innovation at the Massachusetts Institute of Technology.
The alliance, to be known as the Sanofi-Aventis Biomedical Innovation Programme (SABIP), aims to promote scientific exchange between MIT and Sanofi.
It will also provide the French company with the opportunity to develop therapeutic, diagnostic and prognostic applications based any discoveries the alliance makes.
The Centre for Biomedical Innovation’s mission is to improve global health by overcoming obstacles to the development and implementation of biomedical innovation.
Its research focus is on technical, policy, and economic issues related to drug safety, bio-manufacturing, and emerging trends in pharma research and development.
Under the newly announced partnership, the alliance will support a number of activities over the next three years through the granting of ‘Biomedical Innovation Funding Awards’.
Sanofi said that these financial awards will support MIT researchers working on innovative research projects for the development of potential healthcare solutions for patients.
Sanofi’s executive VP of R&D Marc Cluzel said: “As Sanofi-Aventis continues to transform the focus beyond pharmaceuticals to patient healthcare integrated solutions, collaborations like SABIP that promote the exchange of scientific knowledge between academia and industry will play a key role.
“By bringing together the talents and expertise of MIT researchers, who are leaders in engineering and biological sciences, with the resources of Sanofi-Aventis, this alliance has the potential to provide innovative solutions to patients such as new drug delivery devices and technologies.”
Claude Canizares, VP for research and associate provost at the Massachusetts Institute of Technology, said: “MIT and its Centre for Biomedical Innovation are very excited about our collaborative research programme with Sanofi-Aventis.
“MIT brings strengths in advanced science and engineering relevant to healthcare and welcomes the opportunity to work with Sanofi-Aventis on problems of common interest in bio-manufacturing, nanotechnology and other areas.”
Ben Adams
Related Content
Allegro shares promising preclinical results for osteoarthritis treatment
Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in …
MIT-developed algorithm seeks to accelerate drug approvals during COVID-19 pandemic
A study emerging from the Massachusetts Institute of Technology (MIT) and published in the Harvard …
New antibiotic discovered by AI for the first time
MIT researchers have identified a new antibiotic compound using a machine-learning algorithm. In the laboratory …
